Literature DB >> 31594650

The Rome IV: Irritable bowel syndrome - A functional disorder.

Per M Hellström1, Peter Benno2.   

Abstract

Functional gastrointestinal disorders are the most common disorders encountered in the clinical gastroenterology setting. Over the years the Rome process has generated consensus definitions of functional gastrointestinal disorders, and given diagnostic criteria, based on various symptom patterns, that have evolved over the years. The latest Rome IV consensus was presented in May 2016. This summary points out some of the important changes made from the Rome III 2006 consensus including evaluation of symptoms from the stand-point of basal normative values and disorders of gut-brain interaction, as well as additions of the importance of the microflora. However, we are all aware of the fact that there are limitations, and the Rome consensus does not pick up all patients with functional gastrointestinal disorders. Out of those that seek medical help for their functional gastrointestinal symptoms additional outlines of disease have to be considered and judgements made on the patients' actual symptoms, or rather presentation of their symptoms. The Rome IV consensus is a robust standard for a clinical and research approach to functional gastrointestinal disorders, but might be improved by use of exclusion criteria and additional biochemical biomarkers in order to accurately diagnose those patients who may achieve relief by an extended treatment approach in the clinical setting of gastroenterology. A biopsychosocial approach to the patient is recommended to improve compliance and optimize treatment and outcomes.
Copyright © 2019. Published by Elsevier Ltd.

Entities:  

Keywords:  Abdominal pain; Bloating; Constipation; Defecation; Diarrhoea; Stool

Mesh:

Year:  2019        PMID: 31594650     DOI: 10.1016/j.bpg.2019.101634

Source DB:  PubMed          Journal:  Best Pract Res Clin Gastroenterol        ISSN: 1521-6918            Impact factor:   3.043


  7 in total

1.  Relationship Between Systemic Immune-Inflammation Index and Irritable Bowel Syndrome.

Authors:  İbrahim Ethem Güven; Batuhan Başpınar; Roni Atalay
Journal:  Turk J Gastroenterol       Date:  2022-01       Impact factor: 1.555

2.  Cognitive behavioral therapy for irritable bowel syndrome induces bidirectional alterations in the brain-gut-microbiome axis associated with gastrointestinal symptom improvement.

Authors:  Jonathan P Jacobs; Arpana Gupta; Jeffrey M Lackner; Ravi R Bhatt; Jacob Brawer; Kan Gao; Kirsten Tillisch; Venu Lagishetty; Rebecca Firth; Gregory D Gudleski; Benjamin M Ellingson; Jennifer S Labus; Bruce D Naliboff; Emeran A Mayer
Journal:  Microbiome       Date:  2021-11-30       Impact factor: 14.650

3.  Fermentable oligo-, di-, monosaccharides, and polyols (FODMAPs), but not gluten, elicit modest symptoms of irritable bowel syndrome: a double-blind, placebo-controlled, randomized three-way crossover trial.

Authors:  Elise Nordin; Carl Brunius; Rikard Landberg; Per M Hellström
Journal:  Am J Clin Nutr       Date:  2022-02-09       Impact factor: 7.045

4.  Nutraceuticals in the Modulation of the Intestinal Microbiota: Current Status and Future Directions.

Authors:  Enzo Spisni; Silvia Turroni; Patrizia Alvisi; Renato Spigarelli; Demetrio Azzinnari; Dario Ayala; Veronica Imbesi; Maria Chiara Valerii
Journal:  Front Pharmacol       Date:  2022-03-18       Impact factor: 5.810

5.  Clinical study on sequential treatment of severe diarrhea irritable bowel syndrome with precision probiotic strains transplantation capsules, fecal microbiota transplantation capsules and live combined bacillus subtilis and enterococcus faecium capsules.

Authors:  Linling Lv; Guangcong Ruan; Yi Ping; Yi Cheng; Yuting Tian; Zhifeng Xiao; Xuefei Zhao; Dongfeng Chen; Yanling Wei
Journal:  Front Cell Infect Microbiol       Date:  2022-09-28       Impact factor: 6.073

6.  Leveraging 16S rRNA Microbiome Sequencing Data to Identify Bacterial Signatures for Irritable Bowel Syndrome.

Authors:  Yuxia Liu; Wenhui Li; Hongxia Yang; Xiaoying Zhang; Wenxiu Wang; Sitong Jia; Beibei Xiang; Yi Wang; Lin Miao; Han Zhang; Lin Wang; Yujing Wang; Jixiang Song; Yingjie Sun; Lijuan Chai; Xiaoxuan Tian
Journal:  Front Cell Infect Microbiol       Date:  2021-06-11       Impact factor: 5.293

7.  Are patients with polycystic ovary syndrome more prone to irritable bowel syndrome?

Authors:  Małgorzata Kałużna; Pola Kompf; Katarzyna Wachowiak-Ochmańska; Jerzy Moczko; Aleksandra Królczyk; Adam Janicki; Karol Szapel; Marian Grzymisławski; Marek Ruchała; Katarzyna Ziemnicka
Journal:  Endocr Connect       Date:  2022-04-26       Impact factor: 3.221

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.